Revenue Performance - Total revenue for 2024 was $84.6 million, a 15% increase from 2023, primarily driven by a 60% increase in revenue from pharma tests, which reached $50.9 million[340]. - Total revenue for 2024 was $84.6 million, representing a 15% increase from $73.5 million in 2023[362]. - Revenue from pharma tests and services surged by 60% to $50.9 million, driven by increased clinical trial patient enrollments[362][364]. - Enterprise sales revenue decreased by 20% to $25.4 million due to lower average selling prices despite a 7% increase in processed samples[362][365]. - Revenue from Natera, Inc. accounted for 30% of total revenue in 2024, down from 43% in 2023, indicating a diversification in revenue sources[440]. Operational Highlights - The company delivered 3,285 total molecular tests in 2024, a significant increase from 177 tests in the prior year[341]. - The company has the capacity to sequence and analyze over 350 trillion bases of DNA per week, having sequenced approximately 500,000 human samples to date[339]. - The company is focusing on three key indications: breast cancer, lung cancer, and immunotherapy monitoring, supported by collaborations with leading cancer centers and research institutions[338]. - The company commenced commercialization efforts for NeXT Personal Dx with Tempus and expanded collaboration to include marketing to Tempus' pharmaceutical and biotech customers[343]. Financial Position - Cash and cash equivalents increased to $185.0 million in 2024 from $114.2 million in 2023, indicating improved liquidity[360]. - Total assets rose to $270,268,000 in 2024, up from $225,099,000 in 2023, marking an increase of 20%[412]. - Total stockholders' equity increased to $202,957,000 in 2024 from $129,441,000 in 2023, representing a growth of 56.7%[412]. - The company has incurred net losses since inception but believes current cash resources are sufficient to fund operations for at least the next 12 months[386]. Expenses and Cost Management - Total costs and expenses decreased by 17% to $152.9 million, primarily due to workforce reductions and operational efficiencies[369]. - Research and development expenses fell by 25% to $48.9 million, attributed to cost savings from workforce reductions and lower sample processing costs[369][372]. - Selling, general and administrative expenses decreased to $46,187,000 in 2024 from $49,726,000 in 2023, a decline of 7.1%[416]. - The company expects variability in gross margins due to fluctuations in customer mix and volume, but anticipates higher gross margins in the long term as revenue grows[348]. Losses and Cash Flow - Net loss for 2024 was $81.3 million, compared to a net loss of $108.3 million in 2023, reflecting improved operational performance[358]. - Net cash used in operating activities decreased by $11.1 million, or 20%, from $56.3 million in 2023 to $45.2 million in 2024[389]. - The net loss for the year ended December 31, 2024, was $81.284 million, a decrease from a net loss of $108.296 million in 2023, representing a 25% improvement[424]. - Cash used in operating activities decreased to $45.150 million in 2024 from $56.258 million in 2023, reflecting a 20% reduction[424]. Financing Activities - The company raised approximately $35.0 million in net financing proceeds from Tempus, including $18.4 million from the exercise of common stock warrants[343]. - An additional $30.1 million in net proceeds was raised from selling common stock under the At-The-Market (ATM) program at a weighted-average price of $4.61 per share[343]. - Net cash provided by financing activities surged by $103.6 million, or 940%, driven by significant investments from Merck and Tempus[391]. - The Company entered into an investment agreement with Tempus, issuing 3,500,000 shares at $5.07 per share, raising $17.7 million in cash, with $1.1 million in issuance costs[520]. Strategic Changes - The company completed the dissolution of its subsidiary in China in February 2024, indicating a strategic shift in its operational focus[429]. - The Company recorded a lease impairment charge of $5.6 million related to one of its right-of-use assets during the year ended December 31, 2023[469]. - The Company initiated a reduction in workforce affecting nearly 100 employees in January 2023, recognizing $3.1 million in one-time termination benefits[529]. - A second workforce reduction affecting approximately 60 employees was initiated in December 2023, with $4.0 million in one-time termination benefits recognized[530]. Market Development and Collaborations - The Company achieved all three clinical validations for the NeXT Personal Dx test, resulting in $12.0 million in Market Development Fees from Tempus, including a $3.0 million activation fee and milestone payments[512]. - The Tempus Agreement includes co-promotion activities with compensation up to $9.6 million for promotional services through the end of 2026[513]. - The Company invoiced $2.0 million for genomic testing services to Merck, with $2.5 million outstanding as a receivable as of December 31, 2024[526].

Wall Street expects a year-over-year increase in earnings on lower revenues when Personalis (PSNL) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 27. ...

Today’s analysis is going to be a little bit different, in that we’re talking about a cancer-related company. Cancer is something that impacts almost everyone’s life at one time or another. I lost both of my parents to it, and I don’t know manyI’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Magazine and the Quin ...

Personalis (PSNL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earning ...

FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Date of Report (Date of earliest event reported): January 7, 2025 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) 6600 Dumbarton Circle Fremont, California 94555 (Address of Principal Executive Offices) (Zip Code) (Commission File Number) (IRS ...

Personalis (PSNL) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -93.94%. A quarter ago, it was expected that this provider of contract research and genomic information would post a loss of $0.34 per share when it actually produced a loss of $0.24, delivering a surprise of 29.41%.Over the la ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) Delaware 27-5411038 (State or other juri ...

Exhibit 99.1 1 Personalis Reports Third Quarter 2024 Financial Results 41% Year-over-Year Increase in Revenue Driven by Strong Biopharma Growth of 96% Raising 2024 Revenue Guidance Due to Accelerating Growth Cash Balance of $143.7 Million Extends Expected Runway Into First-Half of 2027 FREMONT, Calif. – November 6, 2024 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2024, and provided recent ...

teekid It has been nearly a year since my last Personalis (NASDAQ:PSNL) article, where I provided some background on Personalis and discussed how their NeXT Platform holds immense clinical and commercial potential. At that time, I believed PSNL was undervalued considering the ticker was trading at a negative enterprise value and its long-term growth in a $30B+ market. Over the past 11 months, PSNL went from around $1.61 per share and is now trading over $4.00 per share following encouraging Q2 earnings with ...

Shares of Personalis (PSNL) have been strong performers lately, with the stock up 167.7% over the past month. The stock hit a new 52-week high of $4.58 in the previous session. Personalis has gained 105.2% since the start of the year compared to the 6.7% move for the Zacks Medical sector and the 13.4% return for the Zacks Medical - Generic Drugs industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any ...